The increase in HER2 levels in non-amplified (HER2-low) cancers has therapeutic implications for CNS disease given the efficacy of systemically-delivered HER2-ADCs in both HER2-amplified and HER2-low brain metastases, with trials ongoing in BCLM54,55. Here, ERBB2 is linked to cancer.